FHTX
Foghorn Therapeutics Inc.Company Information
- Company Name
- Foghorn Therapeutics Inc.
- CIK
- CIK0001822462
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- FHTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- FHTX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2024-09-23
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 53,703
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 44,942,234
- Shares outstanding
- 70,629,419
- Ownership
- 63.63%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 7.72%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 68 | 88 | 81 | 89 | 73 | 61 | 55 | 58 | 139 | 79 | 80 | 70 | ||||||
| Marketable Securities | 100 | 96 | 78 | 91 | 126 | 160 | 188 | 210 | 146 | 127 | 154 | 190 | ||||||
| Restricted Cash Current | 0 | 1 | 1 | 1 | 1 | - | 0 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 2 | 3 | 3 | 3 | 4 | 5 | 6 | 4 | 4 | 5 | 6 | 6 | ||||||
| Assets Current | 170 | 188 | 163 | 184 | 204 | 225 | 250 | 271 | 290 | 212 | 240 | 265 | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 1 | 2 | 2 | 9 | 10 | 10 | 10 | 11 | 11 | 12 | 13 | 14 | ||||||
| Restricted Cash Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 30 | 30 | 31 | 10 | 11 | 21 | 23 | 24 | 25 | 29 | 30 | 31 | ||||||
| Assets | 203 | 222 | 198 | 205 | 226 | 259 | 284 | 308 | 329 | 255 | 286 | 313 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 3 | 4 | 3 | 3 | 4 | 4 | 3 | 5 | 6 | 6 | 6 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 8 | 7 | 11 | 10 | 9 | 6 | 9 | 11 | 6 | 6 | 9 | 9 | ||||||
| Operating Lease Liability Current | 3 | 2 | 1 | 7 | 6 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | ||||||
| Contract With Customer Liability Current | 37 | 52 | 43 | 65 | 60 | 52 | 46 | 33 | 31 | 32 | 35 | 28 | ||||||
| Liabilities Current | 51 | 64 | 60 | 85 | 78 | 71 | 67 | 57 | 51 | 52 | 58 | 52 | ||||||
| Operating Lease Liability Noncurrent | 40 | 40 | 40 | 16 | 18 | 26 | 28 | 30 | 28 | 34 | 37 | 39 | ||||||
| Contract With Customer Liability Noncurrent | 193 | 194 | 206 | 193 | 207 | 222 | 234 | 250 | 259 | 266 | 268 | 280 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 1 | 1 | 1 | 1 | 0 | - | - | - | 0 | 0 | ||||||
| Liabilities | 284 | 299 | 307 | 295 | 303 | 320 | 330 | 337 | 343 | 352 | 363 | 371 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 579 | 576 | 524 | 521 | 518 | 515 | 513 | 510 | 506 | 400 | 395 | 392 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | -1 | -2 | ||||||
| Retained Earnings Accumulated Deficit | -660 | -652 | -632 | -611 | -595 | -577 | -558 | -539 | -520 | -497 | -472 | -447 | ||||||
| Stockholders Equity | -81 | -76 | -109 | -90 | -77 | -62 | -46 | -28 | -14 | -97 | -77 | -57 | ||||||
| Liabilities And Stockholders Equity | 203 | 222 | 198 | 205 | 226 | 259 | 284 | 308 | 329 | 255 | 286 | 313 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 175 | 175 | 175 | 175 | 175 | 175 | 175 | 175 | 175 | 175 | 175 | 175 | ||||||
| Common Stock Shares Issued | 59 | 59 | 57 | 57 | 56 | 56 | 56 | 56 | 55 | 43 | 42 | 42 | ||||||
| Shares Outstanding | 59 | 59 | 57 | 57 | 56 | 56 | 56 | 56 | 55 | 43 | 42 | 42 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialFoghorn Therapeutics Inc. (FHTX) — SEC Financial Statements & Analysis
Foghorn Therapeutics Inc. (FHTX) is a pharmaceutical preparations company, incorporated in DE. Foghorn Therapeutics Inc. trades on Nasdaq as: FHTX. Foghorn Therapeutics Inc. (FHTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Foghorn Therapeutics Inc. carries a market cap of $344.67M, a P/E ratio of -5.34x, a P/B ratio of -4.25x, a P/S ratio of 9.38x, an enterprise value of $274.59M, and an EV/EBITDA multiple of -3.88x. On profitability, it posts an operating margin of -198.04%, a net margin of -175.78%, a Return on Equity (ROE) of 81.90%, and a Return on Assets (ROA) of -30.06%. Per share, it reports EPS of $-0.91, diluted EPS of $-0.91, free cash flow per share of $-1.19, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 51.98% year-over-year, net income growth of -14.35% year-over-year, and EPS growth of -23.62% year-over-year. On the balance sheet, it maintains a current ratio of 3.36x, a quick ratio of 3.31x, working capital of $119.47M, a debt-to-equity ratio of -3.51x, a debt ratio of 1.4, free cash flow of $-84.29M (TTM), and net debt of $-70.08M. Figures sourced from SEC EDGAR.
- Market Cap
- $344.67M
- P/E TTM
- -5.34x
- EPS TTM
- $-0.91
- P/B TTM
- -4.25x
- ROE TTM
- 81.90%
- ROA TTM
- -30.06%
- Debt To Equity
- -3.51x
- Free Cash Flow TTM
- $-84.29M
- Net Revenue TTM Growth 1Y
- 51.98%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Foghorn Therapeutics Inc. in?
Foghorn Therapeutics Inc. (FHTX) operates in the Pharmaceutical Preparations industry.
What exchange does FHTX trade on?
Foghorn Therapeutics Inc. (FHTX) trades on the Nasdaq.
Where is Foghorn Therapeutics Inc. incorporated?
Foghorn Therapeutics Inc. is incorporated in DE.
When was Foghorn Therapeutics Inc. (FHTX)'s most recent SEC filing?
Foghorn Therapeutics Inc. (FHTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is FHTX's market cap?
Foghorn Therapeutics Inc. (FHTX) has a market capitalization of $344.67M as of 2026-06-30.
What is FHTX's EPS (earnings per share)?
Foghorn Therapeutics Inc. (FHTX)'s trailing twelve month EPS is $-0.91 as of 2026-06-30.
What is FHTX's ROE (return on equity)?
Foghorn Therapeutics Inc. (FHTX)'s trailing twelve month Return on Equity (ROE) is 81.90% as of 2026-06-30.
What is FHTX's ROA (return on assets)?
Foghorn Therapeutics Inc. (FHTX)'s trailing twelve month Return on Assets (ROA) is -30.06% as of 2026-06-30.
What is FHTX's EV/EBITDA?
Foghorn Therapeutics Inc. (FHTX)'s trailing twelve month EV/EBITDA is -3.88x as of 2026-06-30.